Natco Pharma acquires Adcock Ingram, expands in Africa

Axplora, a Germany-headquartered contract development and manufacturing organization (#CDMO) specializing in small molecule active pharmaceutical ingredients (APIs), announced plans to invest more than €100 million (approximately $108 million) across its international network in 2025, according to the company. The investment includes approximately €60 million ($65 million) for an ongoing expansion at its Mourenx, France site, €35 million ($38 million) at Gropello, Italy, and €8.5 million ($9 million) at Vizag, India. Earlier this year, Axplora also expanded antibody-drug conjugate (#ADC) manufacturing capabilities at its Le Mans, France, facility. Read more: https://lnkd.in/gStnyjzi #PharmaManufacturing #APIMarket #CDMOs #GlobalExpansion #SmallMoleculeAPIs #ADCs #PharmaOperations #ManufacturingInvestment #Axplora #PharmaceuticalManufacturing #Pharmaceuticals #ActivePharmaceuticalIngredients

Qiming Venture Partners' portfolio company Gan & Lee Pharmaceuticals (SHSE:603087) has officially signed a 10-year Technology Transfer and Supply Agreement with Fiocruz1, a public laboratory, and Biomm, a leading Brazilian biopharmaceutical company. This marks the formal launch of Brazil's Parcerias para o Desenvolvimento Produtivo (PDP) project.   At the same time, Gan & Lee Pharmaceuticals entered into a new Licensing and Supply Agreement with Biomm, securing cumulative orders of no less than RMB 3 billion over ten years, setting a new milestone on the foundation of strategic cooperation. #Biopharma #Pharmaceuticals #GlobalHealthcare #StrategicPartnership #LicensingAgreement #HealthcareInnovation #QimingPortfolio #QimingHealthcare

Rubicon Research to launch INR 1,377.5-cr IPO on Oct 9 Rubicon focuses on pharmaceutical formulations, R&D and innovation, specializing in specialty products and drug-device combinations for regulated markets, especially the US. The company recently expanded its manufacturing base by acquiring Alkem Laboratories’ facility in Madhya Pradesh. https://lnkd.in/de53JUWY Automated feed updates

Pakistan’s Pharmaceutical Exports Reach Two-Decade High. Special Assistant to the Prime Minister (SAPM) on Industries and Production Haroon Akhtar Khan attended the 8th Pakistan Pharma Summit as the Chief Guest and addressed participants of both the Summit and the Pharma Export Awards Ceremony. Read More https://lnkd.in/dXEnnrr8 #HaroonAkhtarKhan #SAPM #PakistanPharmaSummit

Pharma firms shift to direct-to-consumer model with price cuts Several major pharmaceutical companies announced plans to sell certain drugs directly to patients in the U.S., alongside price reductions. This follows pressure from the Trump administration to lower drug costs. #pharma #businessModel #pricing

AUROBINDO PHARMA LTD has announced the incorporation of a new wholly owned subsidiary in Malaysia to expand its pharmaceutical products business in the country. Read more : https://lnkd.in/d_bEWKpu #AurobindoPharma #PharmaExpansion #MalaysiaMarket #Pharmaceuticals #GlobalPharma #HealthcareInnovation

Accoridng to CNN, the 100% drug tariff impact is limited due to various reasons, most notably 1. trade deals and 2. many pharmaceutical companies are already in the process of building up facilities in the United States https://lnkd.in/gKRkrFf4

"President Donald Trump announced Thursday that brand-name or patented pharmaceutical products will be subject to a 100% tariff starting Oct. 1 unless the pharmaceutical company is building a manufacturing plant in the United States, per a CNN report. The report pointed out that Trump views tariffs as a way to pressure drug manufacturers to increase production in the United States and to strengthen the supply chain for essential medicines, as well as to keep his pledge to lower drug costs, though experts say that is unlikely to happen, per the report." Read more at: https://bit.ly/47eM3qK 

𝐌𝐎𝐃𝐎𝐍 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐒𝐀𝐑𝟑𝟕𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐒𝐮𝐝𝐚𝐢𝐫. Saudi Arabia’s MODON signed a SAR375 million contract with France’s BPI to establish advanced pharmaceutical facilities in Sudair Industrial and Business City, boosting local industry and innovation. #SaudiArabia #MODON #Sudair #Pharmaceuticals #MedicalInvestment #Industry #Innovation #Healthcare #EconomicGrowth #ArabTimesNews